* A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at
Closing.
* Expected breakthroughs by combining technologies in (early) cancer detection

    and recurrence of cancer with a single vial of blood.
  * Cyclomics' 4th generation liquid biopsy genomics platform is a truly "Omni-
    Omic" blood test ready for AI application
  * GEDiCube's award-winning AI is developing high-performance biomarker panels
    for 13 different cancers.
  * GEDiCube's partnership with NVIDIA's Inception program will help expand to
    multi-modal capabilities by adding imaging.

The combined Companies aim to Disrupt Cancer Diagnosis and treatment through
early disease and recurrence detection, prediction of response to treatment, and
personalized therapy.
LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) -- GEDi Cube Intl Ltd., a London and
Netherlands-based advanced AI company and a wholly owned subsidiary of Renovaro
Inc. (NASDAQ: RENB), announces it has executed a binding Letter of Intent (LOI)
to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the
parties have agreed to work in good faith on the drafting of a definitive
agreement.
Cyclomics has developed a groundbreaking diagnostic method for monitoring early
cancer recurrence named "CyclomicsSeq"- a novel ctDNA (circulating tumor DNA is
tumor-derived fragmented DNA in the bloodstream that is not associated with
cells) detection assay based on Oxford Nanopore sequencing which delivers fast,
low-cost, and point-of-care sequencing. In contrast to available ctDNA-based
methods, "CyclomicsSeq" ensures that even a single ctDNA molecule in the blood
can be detected at very high accuracy. This solution consists of a new
diagnostic kit (CyclomicsSeq), which has been licensed to Oxford Nanopore (LON:
ONT), an RNA/DNA next-generation sequencing platform company.
Cyclomics' Omni-Omic 4th generation technology, we believe, will disrupt the
cancer diagnostics market and clinical practice by enabling fast and reliable
results and delivering superior performance to standard radiological and
physical examination alone. The platform is expected to enable reliable, fast,
and ultra-sensitive early/recurrence detection of cancer using the next-
generation whole genome sequencing. That is achieved by detecting ctDNA, a
reliable biomarker for determining the presence or absence of cancer, which can
be non-invasively obtained from a blood sample (liquid biopsy). The novel
approach to cancer detection is based on a single vial of blood and multi-
dimensional profiling. Cyclomics applies a wide multi-signal/multi-omics
approach to a very low amount of tumor ctDNA. The Omni-Omic approach is critical
for early cancer detection with high accuracy.
Radiological imaging is the current standard in detecting tumor recurrence, but
it suffers from low sensitivity and specificity, very often revealing relapsed
cancer when it has progressed too far for effective treatment strategies. Fast
non-invasive treatment response monitoring is critical for cancer patients to
timely adjust drug doses or change drug choices.
Cyclomics has already developed an early detection technology called
"CyclomicsSeq TP53", an in vitro diagnostic (IVD) kit integrating an innovative
sequencing methodology and state-of-the-art analysis software. Ninety percent of
Head Neck Cancer (HNC) patients carry specific oncogenic DNA mutations in the
gene TP53. There are 150,000 new cases every year in the EU and nearly 70,000 in
the USA. The Cyclomics solution can be applied to other cancer types harboring
TP53, such as small-cell lung cancer, squamous cell lung cancer, triple-negative
breast cancer, and high-grade serous ovarian cancer, and can be expanded to
almost all cancer types.
GEDiCube's platform technology deploys next-generation AI running on NVIDIA's
latest chips and stacks genetic and protein expression on top of DNA mutation
for accuracy in cancer detection. GEDiCube is focused on developing advanced
diagnostic and monitoring tests that use multi-omics, integrating data from each
stage of genetic expression, including genomics, epigenomics, transcriptomics,
proteomics, fragmentomics and metabolomics. As a member of the Nvidia Inception
Program, the company will integrate medical imaging into its AI engine.
Upon closing, the combined companies will aim to accelerate entry into the
cancer monitoring market and gain access to integrating whole genome data into
GEDiCube's AI/Machine Learning platform.
"We are very excited about this new opportunity," said Alessio Marcozzi, PhD,
co-founder of Cyclomics. "Our Omni-Omic technology was developed to help empower
AI platforms and thereby transform non-invasive healthcare solutions to detect
cancers and other diseases as early as possible. GEDiCube's innovative deep
learning algorithms have created robust multi-omics panels that perform
remarkably well. Together, I believe we will change the field." Coenraad van
Kalken, MD, PhD, the CEO of GEDiCube, commented, "There is enormous power in
applying AI to multiple omics data layers that can be detected from a vial of
blood from every patient with cancer. I believe that integrating Cyclomics into
GEDiCube will allow us to gain greater accuracy and widespread Omni-omic
measurements through next-generation sequencing and enter the cancer monitoring
market this year. I consider that to be a significant step towards bringing
early detection of cancer to its inflection point."
About Cyclomics
Cyclomics is a Dutch company founded in 2018, winner of the Health Holland
Venture Challenge (startup of the year) by scientists of the UMC Utrecht
(https://www.umcutrecht.nl/). Its ambition is to transform cancer care by
enabling faster and more reliable diagnoses, particularly in the context of
cancer recurrence, thanks to its proprietary circulating tumor DNA (ctDNA
(https://en.wikipedia.org/wiki/Circulating_tumor_DNA)) detection technology.
About GEDiCube
At GEDiCube, we are committed to the early detection of cancer, to intervene at
a stage where treatment can be most effective. We have developed an award-
winning AI Technology that significantly accelerates early cancer detection and
diagnosis at an early stage and its recurrence via liquid biopsy. Our platform,
" The Cube," brings together proprietary artificial intelligence (AI/ML)
technology and algorithms, multi-omics, multi-modal data, and the expertise of a
carefully selected multidisciplinary team to accelerate precision medicine and
enable breakthrough changes in cancer care. As of this morning GEDiCube will
operate under its new name, RenovaroCube.
About Renovaro
Renovaro aims to accelerate precision, personalized medicine for longevity
powered by mutually reinforcing AI and biotechnology platforms for early
diagnosis, better-targeted treatments, and drug discovery. Renovaro includes
RenovaroCube and Renovaro Biosciences.
Renovaro Biosciences is an advanced cell-gene-immunotherapy company. Its lead
candidate product is a therapeutic vaccine targeting cancers which are difficult
to treat including pancreatic and potentially HNC, triple-negative breast
cancer, and advanced liver cancer. However, the vaccine could potentially work
for all solid tumors and chronic infectious diseases such as HIV and Hepatitis B
Virus.
FORWARD-LOOKING STATEMENTS
Statements in this press release that are not strictly historical in nature are
forward-looking statements. These statements are only predictions based on
current information and expectations and involve a number of risks and
uncertainties, including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are forward-looking
statements, which can be identified by the use of forward-looking terminology
such as "believes," "plans," "expects," "aims," "intends," "potential," or
similar expressions. Actual events or results may differ materially from those
projected in any of such statements due to various uncertainties, including as
set forth in Renovaro's most recent Annual Report on Form 10-K and its
definitive proxy statement related to the acqusition of GEDi Cube Intl Ltd.
filed with the SEC. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All forward-
looking statements are qualified in their entirety by this cautionary statement,
and Renovaro Inc. undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date hereof.
Contact: ir@renovarobio.com (mailto:ir@renovarobio.com)
Source: Renovaro Biosciences
Â